Obesity, anti-obesity medications, and atrial fibrillation: Recent advances
Ожирение, препараты для лечения ожирения и фибрилляция предсердий: последние достижения
2026-03-27
SCID: 54.1/cyrbxqbf
Discuss with AI
GLP-1 receptor agonistsatrial fibrillationatrial remodelingepicardial adipose tissueobesity
Figures from the paper
Abstract (AI)
Obesity and atrial fibrillation (AF) are closely connected conditions that share many metabolic, hemodynamic,and inflammatory pathways. An increasing body mass index is linked to incident AF, AFprogression, and higher recurrence rates after cardioversion or catheter ablation. Notably, obesitycontributes to atrial structural and electrical remodeling through various mechanisms, includingsystemic inflammation, oxidative stress, epicardial adipose tissue buildup, metabolic dysregulation,and changes in calcium handling and connexin expression. These alterations create a proarrhythmicsubstrate that promotes AF initiation and maintenance. Sustained weight loss has been strongly associated with reverse atrial remodeling, improved hemodynamics, decreased AF burden, and lower recurrence rates. In this evolving treatment landscape, anti-obesity pharmacotherapy, particularly glucagon-like peptide-1 receptor agonists (GLP-1RA), has emerged as a promising supplementary strategy. Beyond weight reduction and blood sugar control, these medications have pleiotropic cardiovascular effects, such as anti-inflammatory and antioxidant actions, hemodynamic improvements, decreases in epicardial adipose tissue, and reductions in atrial fibrosis. Several observationalstudies and meta-analyses suggest that GLP-1RA lower the risk of new-onset AF and AF recurrenceafter cardioversion or ablation. However, most available data come from studies in which AF wasa secondary endpoint, involving diverse populations and relatively short follow-up periods. Whileanti-obesity drugs - especially GLP-1RA - show significant potential to influence AF risk andprogression, conclusive evidence requires well-powered, randomized controlled trials with AF asthe primary endpoint, standardized arrhythmia monitoring, and long-term follow-up.
Key Findings
1
Current evidence for GLP-1 receptor agonists is limited because AF was usually a secondary endpoint, follow-up was short, and populations were heterogeneous; definitive randomized trials are needed.
2
GLP-1 receptor agonists may reduce AF risk and recurrence through weight loss and pleiotropic effects, including anti-inflammatory, antioxidant, hemodynamic, and antifibrotic actions.
3
Higher body mass index is associated with incident atrial fibrillation, AF progression, and increased recurrence after cardioversion or catheter ablation.
4
Obesity promotes a proarrhythmic atrial substrate through inflammation, oxidative stress, epicardial adipose accumulation, metabolic dysregulation, and altered calcium handling and connexin expression.
5
Sustained weight loss is associated with reverse atrial remodeling, improved hemodynamics, reduced AF burden, and lower recurrence rates.
Research Object
Obesity-associated atrial fibrillation and anti-obesity pharmacotherapy, particularly GLP-1 receptor agonists
Research Subject
The effects and mechanisms of obesity, weight loss, and anti-obesity medications on atrial remodeling, AF initiation and progression, AF burden, and recurrence risk
Publication Details
Publication Date
2026-03-27
Journal
Publisher
ISSN
Cited by
4
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest